Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966

Integrin β1 receptor, expressed on the surface of tumor cells and macrophages in the tumor microenvironment (TME), has been implicated in both tumor progression as well as resistance to multiple modalities of therapy. OS2966 is the first clinical-ready humanized monoclonal antibody to block integrin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Lee, Tae Jin, Nair, Mitra, Banasavadi-Siddegowda, Yeshavanth, Liu, Joseph, Nallanagulagari, Tejaswini, Jaime-Ramirez, Alena Cristina, Guo, Jeffrey Yunhua, Quadri, Haroon, Zhang, Jianying, Bockhorst, Kurt H, Aghi, Manish K, Carbonell, W. Shawn, Kaur, Balveen, Yoo, Ji Young
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6548661/
https://ncbi.nlm.nih.gov/pubmed/30926634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0953
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi